Axim is an actively involved company in the research and development of innovative cannabinoid products for the use of pharmaceutical purposes. MedChewRx is a new pharmaceutical, functional chewing gum containing cannabinoids. With clinical studies going on world wide, this chewing gum is the first of its kind. The gum is designed to relieve patient’s chronic pain, as well as treating spasticity in patients with multiple sclerosis. Axim is conducting their research to the strict protocols of the FDA/ EMA guidelines, and are hoping to have the product available by 2018.
With the rise of cannabis oil becoming an alternative medicine for pain relief, patients are looking for new methods beyond the traditional pipe or paper. What makes CBD hemp oil so popular is that it is made up of high-CBD, low-THC hemp. Unlike medicinal marijuana products, which are made from high concentrations of psychoactive tetrahydrocannabinol, or THC, hemp contains small traces of THC, making them non-psychoactive.
The hope in releasing MedChewRx is to provide a healthier alternative to inhaling cannabis smoke. It is also more “socially acceptable” opposed to smoking. The chewing gum is digested directly in the mouth and bypasses the liver, giving a quicker relief to the pain. This will allow patients to be able to take smaller doses, and they will not have to worry about getting high.
If you would like to know more about what CBD hemp oil is and all the benefits it can provide in the pharmaceutical department, check out this article.
This article was inspired by content found here.